Skip to main content
. 2021 Apr 26;13(8):12129–12142. doi: 10.18632/aging.202923

Figure 5.

Figure 5

MiR-1297 inhibited proliferation, migration and invasion in glioma cells by targeting EZH2. (A) EZH2 was predicted as a target of miR-1297 through online bioinformatic databases. (B) Expression of EZH2 in normal tissues (n=7) and glioma tissues (n=17). (C) Expression of EZH2 in normal human astrocytes and glioma cell lines based on qRT-PCR. (D–F) qRT-PCR and western blotting showing the expression of EZH2 in glioma cell lines transfected with NC, sh-EZH2, miR-1297 or miR-1297 together with the EZH2 plasmid. (G, H) Luciferase reporter assays showed that miR-1297 reduced the luciferase activity of EZH2-WT but not of EZH2-MUT. (I, J) CCK-8 assays showing the proliferative capacity of glioma cell lines transfected with NC, sh-EZH2, miR-1297 or miR-1297 together with the EZH2 plasmid. (K, L) Colony formation assays showing the proliferative capacity of glioma cell lines transfected with NC, sh-EZH2, miR-1297 or miR-1297 together with the EZH2 plasmid. (M–P) Transwell assays showing the migration and invasion of glioma cell lines transfected with NC, sh-EZH2, miR-1297 or miR-1297 together with the EZH2 plasmid. *p < 0.05, **p < 0.01.